Comment from Children's Hospital Association

Summary: The Children's Hospital Association supports the FDA's draft guidance but urges the agency to incorporate specific considerations for pediatric patients, including safety, delivery protocols, and reimbursement frameworks. They advocate for partnerships with children's hospitals and the inclusion of pediatric experts in the regulatory process to ensure equitable and sustainable access to rare disease therapies.